-
Off-Topic Alert: Breast Implants Lymphoma Cancer ALCL Case Numbers Increasing Rapidly in the US
New Estimates Reported in July 2022 Medical Journal Article Reveal BIA-ALCL is Diagnosed More Often as Time Goes On (Posted by Tom Lamb at Drug Injury Watch) A research letter published July 21, 2022 in…
-
Using Copiktra for Leukemia or Lymphoma May Increase Risks of Serious Side Effects and Death
Future FDA Advisory Committee Meeting Will Discuss Whether Copiktra Should be Used as CLL or SLL Treatment (Posted by Tom Lamb at Drug Injury Watch) As background, Copiktra (duvelisib) was approved by the FDA in…
-
Xalkori Vision Side Effects for Pediatric Patients in Clinical Trials Were Seen at an Alarming Rate, Says EMA
Drug Safety Warning: Xalkori-Related Ocular Toxicity and Severe Visual Loss are Difficult to Detect in Children (Posted by Tom Lamb at Drug Injury Watch) Xalkori (crizotinib) is approved by the FDA for the treatment of:…
-
New FDA Regulatory Action for Ukoniq Recall First Announced by Drug Company in April 2022
June 2022 FDA Drug Safety Communication Makes Clear That Ukoniq Was Removed From Market Due to Safety Issues (Posted by Tom Lamb at Drug Injury Watch) On June 1, 2022, the FDA issued an update…
-
Ukoniq Drug Recall in April 2022 Comes Soon After FDA Warning About Increased Risk of Death in February 2022
This "New" Lymphoma Drug Had Only Been on the Market Since February 2021, When Ukoniq Received FDA Accelerated Approval (Posted by Tom Lamb at Drug Injury Watch) In February 2022 we wrote about this Drug…